Graft-versus-leukemia effects of transplantation and donor lymphocytes

Blood

Volumn 112, Issue 12, 2008, Pages 4371-4383

  Kolb, Hans Jochem ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTILEUKEMIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; IMMUNOSUPPRESSIVE AGENT; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CELLULAR IMMUNITY; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HISTOCOMPATIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LEUKEMIA; LOW DRUG DOSE; LYMPHOMA; MEMORY T LYMPHOCYTE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROGENY; RECURRENT CANCER; REMISSION; T LYMPHOCYTE; THERAPY EFFECT; TUMOR CELL; VIRUS INFECTION; ADOPTIVE IMMUNOTHERAPY; BLOOD DONOR; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE; LYMPHOCYTE TRANSFUSION; METHODOLOGY; MORTALITY; PHYSIOLOGY; REVIEW; TUMOR ESCAPE;

ANTINEOPLASTIC AGENTS; BLOOD DONORS; GRAFT VS HOST DISEASE; GRAFT VS HOST REACTION; GRAFT VS LEUKEMIA EFFECT; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES; PIPERAZINES; PYRIMIDINES; TRANSPLANTATION IMMUNOLOGY; TUMOR ESCAPE;

EID: 58149384550     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-077974     Document Type: Article

References (169)

1. Burchenal JH, Oettgen HF, Holmberg EA, Hemphill SC, Reppert JA. Effect of total-body irradiation on the transplantability of mouse leukemias. Cancer Res. 1960;20:425-430.
2. Barnes DHW, Loutit JF. Treatment of murine leukaemia with X-rays and homologous bone marrow. Br J Haematol. 1957;3:241-252.
3. Mathé G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M. Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res. 1965;25:1525-1530.
4. Thomas ED, Storb R, Clift RA, et al. Bone marrow transplantation. N Engl J Med. 1975;292:832-843.
5. Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation and allogeneic marrow transplantation. Blood. 1977;49:511-533.
6. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effects of graft versus host disease in human recipients of allogeneic marrow grafts. N Engl J Med. 1979;300:1068-1070.
7. Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allo-geneic marrow transplantation. N Engl J Med. 1981;304:1529-1531.
8. Rodt H, Kolb HJ, Netzel B, et al. GVHD suppression by incubation of bone marrow grafts with anti-T-cell globulin: effect in the canine model and application to clinical bone marrow transplantation. Transplant Proc. 1979;11:962-966.
9. Kolb HJ, Rieder I, Rodt H, et al. Antilymphocytic antibodies and marrow transplantation: VI. Graft-versus-host tolerance in DLA-incompatible dogs after in vitro treatment of bone marrow with absorbed antithymocyte globulin. Transplantation. 1979;27:242-245.
10. Apperley JF, Mauro FR, Goldman JM, et al. Bone marrow transplantation for chronic myeloid leukemia in first chronic phase: importance of a graft-versus-leukemia effect. Br J Haematol. 1988;69: 239-245.
11. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
12. Weiden PL, Storb R, Tsoi M-S, et al. Infusion of donor lymphocytes into stable canine radiation chimeras: implications for mechanism of transplantation tolerance. J Immunol. 1976;116:1212-1219.
13. Kolb HJ, Günther W, Schumm M, et al. Adoptive immunotherapy in canine chimeras. Transplantation. 1997;63:430-436.
14. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462-2465.
15. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 1996;87:2195-2204.
16. Giralt S, Cohen A, Mehra R, et al. Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation (ALLO-PCT) in poor candidates for conventional myeloablative conditioning [abstract]. Blood. 1997;90:417a.
17. McSweeney PA, Wagner JL, Maloney DG, et al. Outpatient PBSC allografts using immunosup-pression with low dose TBI before, and cyclosporin (CSP) and mycophenolate mofetil (MMF) after transplant [abstract]. Blood. 1998;92:519a. Abstract 2133.
18. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med. 1990;323:315-321.
19. Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 2002;100:3108-3114.
20. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev. 1997;157:125-130.
21. Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood. 1998;91:2197-2207.
22. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer. 2004;4:371-380.
23. Marijt WA, Heemskerk MHM, Kloosterboer FM, et al. Hematopoiesis- restricted minor histocompatibility antigens HA-1 or HA-2-specific T cells can induce complete remissions of relapsed acute leukemia. Proc Natl Acad Sci USA. 2003;100: 2742-2747.
24. Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med. 2002;8:575-581.
25. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80: 2964-2968.
26. Ferrara JLM, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324:667-674.
27. Holler E, Kolb HJ, Mittermüller J, et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor (TNF) release in the course of pre-transplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF (MAK 195F). Blood. 1995;86:890-899.
28. Ridge JP, Di Rosa F, Matzinger P. Aconditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell [see comments]. Nature. 1998;393:474-478.
29. Chakraverty R, Eom HS, Sachs J, et al. Host MHC class II + antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood. 2006;108:2106-2113.
30. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412-415.
31. Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med. 2004;10:987-992.
32. Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood. 1996;88:1501-1508.
33. Smit WM, Rijnbeck M, van Bergen CAM, et al. Dendritic cells generated from FACS sorted chronic myeloid leukemia (CML) precursor cells express BCR/ABL, and are potent stimulators for allogeneic T cells [abstract]. Br J Haematol. 1996; 93:313a. Abstract 1186.
34. Chen X, Regn S, Kolb H-J, Roskrow M. The generation of leukemic dendritic cells from patients with chronic myeloid leukemia (CML) using the combination of interferon-a and GM-CSF [abstract]. Blood. 1999;94:529a.
35. Clark RE, Dodi IA, Hill SC, et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood. 2001;98:2887-2893.
36. Mittermueller J, Kolb HJ, Gerhartz HH, Wilmanns W. In vivo differentiation of leukemic blasts and effect of low dose ara-c in a marrow grafted patient with leukemic relapse. Br J Haematol. 1986; 62:757-762.
37. Schmetzer HM, Kremser A, Loibl J, Kroell T, Kolb HJ. Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in vivo. Leukemia. 2007;21:1338-1341.
38. Woiciechowsky A, Regn S, Kolb H-J, Roskrow M. Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukaemia-specific cytotoxic T cell response from patients with acute myeloid leukaemia. Leukemia. 2001;15:246-255.
39. Chen X, Regn S, Raffegerst S, Kolb HJ, Roskrow M. Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia. Br J Haematol. 2000;111:596-607.
40. Johnson BD, Becker EE, LaBelle JL, Truitt RL. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy. J Immunol. 1999;163:6479-6487.
41. Blazar BR, Lees CJ, Martin PJ, et al. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. J Immunol. 2000;165: 4901-4909.
42. Johnson BD, Konkol MC, Truitt RL. CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT Biol Blood Marrow Transplant. 2002;8:525-535.
43. Miller JS, Weisdorf DJ, Burns LJ, et al. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood. 2007; 110:2761-2763.
44. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041-2050.
45. Dolstra H, Fredrix H, Maas F, et al. Ahuman minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med. 1999; 189:301-308.
46. Warren EH, Gavin MA, Simpson E, et al. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J Immunol. 2000;164:2807-2814.
47. Gao L, Xue SA, Hasserjian R, et al. Human cytotoxic T lymphocytes specific for Wilms' tumor anti-gen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation. 2003;75:1429-1436.
48. Molldrem J, Dermime S, Parker K, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 1996;2450-2457.
49. Greiner J, Schmitt M, Li L, et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood. 2006;108:4109-4117.
50. Mailander V, Scheibenbogen C, Thiel E, et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia. 2004;18:165-166.
51. Stauss HJ. Immunotherapy with CTLs restricted by nonself MHC. Immunol Today. 1999;20:180-183.
52. Hertenstein B, Wiesneth M, Novotny J, et al. Interferon alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic marrow transplantation [abstract]. Transplantation. 1993;56:1114-1118.
53. Helg C, Roux E, Beris P, et al. Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant. 1993;12:125-129.
54. Bar BMAM, Schattenberg A, Mensink EJBM, et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol. 1993;11:513-519.
55. Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994;330:100-106.
56. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
57. Bacigalupo A, Soracco M, Vassallo F, et al. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;19:927-932.
58. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995;86: 4337-4343.
59. Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998;91: 3671-3680.
60. Orsini E, Bellucci R, Alyea EP, et al. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Cancer Res. 2003;63:2561-2568.
61. Bonini C, Verzelletti S, Servida P, et al. Transfer of HSV-TK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity after allo-BMT [abstract]. Blood. 1994;84[Suppl]:110a.
62. Ciceri F, Bonini C, Gallo-Stampino C, Bordignon C. Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation. Cytotherapy. 2005;7:144-149.
63. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995;86:1261-1268.
64. Guglielmi C, Arcese W, Dazzi F, et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood. 2002;100:397-405.
65. Lewalle P, Triffet A, Delforge A, et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant. 2003;31:39-44.
66. Kolb HJ, Rank A, Chen X, et al. In-vivo generation of leukaemia-derived dendritic cells. Best Pract Res Clin Haematol. 2004;17:439-451.
67. Cummins M, Cwynarski K, Marktel S, et al. Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT). Bone Marrow Transplant. 2005;36:1065-1069.
68. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
69. Kantarjian HM, O'Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2002;100:1590-1595.
70. Olavarria E, Craddock C, Dazzi F, et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood. 2002;99:3861-3862.
71. Weisser M, Tischer J, Schnittger S, et al. Acom-parison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica. 2006; 91:663-666.
72. Weisser M, Schleuning M, Haferlach C, Schwerdtfeger R, Kolb HJ. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma. 2007;48:295-301.
73. Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barrett AJ. Imatinibsynergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant. 2005;36:1009-1015.
74. Burchert A, Wolfl S, Schmidt M, et al. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood. 2003;101:259-264.
75. Appel S, Boehmler AM, Grunebach F, et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood. 2004;103: 538-544.
76. Cwynarski K, Laylor R, Macchiarulo E, et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia. 2004;18: 1332-1339.
77. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004;104:1094-1099.
78. Wang H, Cheng F, Cuenca A, et al. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood. 2005;105:1135-1143.
79. Chen J, Schmitt A, Giannopoulos K, et al. Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. Int J Oncol. 2007;31:1133-1139.
80. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003;101:4701-4707.
81. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107: 4532-4539.
82. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109:58-60.
83. Schmid C, Schleuning M, Aschan J, et al. Low dose ara-c, donor cells and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation: a pilot study. Leukemia. 2004;18:1430-1433.
84. Dermime S, Mavroudis D, Jiang YZ, et al. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;19:989-999.
85. Brouwer RE, Hoefnagel J, Borger van Der BB, et al. Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis. Br J Haematol. 2001;115:298-308.
86. Kufner S, Zitzelsberger H, Kroell T, et al. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions. Scand J Immunol. 2005;62:86-98.
87. Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007;25: 4938-4945.
88. Levine JE, Braun T, Penza SL, et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol. 2002;20:405-412.
89. Campregher PV, Gooley T, Scott BL, et al. Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. Bone Marrow Transplant. 2007;40:965-971.
90. Pollyea DA, Artz AS, Stock W, et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007;40:1027-1032.
91. Porter DL, Roth MS, Lee SJ, et al. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996; 18:975-980.
92. Depil S, Deconinck E, Milpied N, et al. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. Bone Marrow Transplant. 2004;33: 531-534.
93. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2006; 108:1092-1099.
94. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23:5675-5687.
95. Shiobara S, Nakao S, Ueda M, et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant. 2000;26:769-774.
96. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103:767-776.
97. Nijmeijer BA, Willemze R, Falkenburg JH. An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/ scid mice. Blood. 2002;100:654-660.
98. Cardoso AA, Schultze JL, Boussiotis VA, et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood. 1996; 88:41-48.
99. Corradini P, Tarella C, Olivieri A, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood. 2002;99:75-82.
100. Herbert KE, Spencer A, Grigg A, et al. Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transplant. 2004; 34:521-525.
101. Passweg JR, Tiberghien P, Cahn JY, et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant. 1998;21:153-158.
102. Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005;106:4389-4396.
103. Ritgen M, Stilgenbauer S, von Neuhoff N, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood. 2004;104:2600-2602.
104. Bierman PJ, Sweetenham JW, Loberiza FR Jr, et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation. The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2003;21:3744-3753.
105. Grigg A, Ritchie D. Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant. 2004; 10:579-590.
106. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004;104:3535-3542.
107. Khouri IF. Reduced-intensity regimens in allogeneic stem-cell transplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2006;390-397.
108. Peggs KS, Thomson K, Hart DP, et al. Dose escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004;103: 1548-1556.
109. Bloor AJ, Thomson K, Chowdhry N, et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:50-58.
110. Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87:1196-1198.
111. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EF. Graft-versus-myeloma effect in two cases. Lancet. 1996;347:800-801.
112. Diez-Martin JL, Penalver FJ, Gonzalez-Hurtado JA, et al. Double infusion of donor leukocytes (DLI) to treat relapsed multiple myeloma after an allogeneic bone marrow transplantation [abstract]. Bone Marrow Transplant. 1997;19[suppl]: 178.
113. Salama M, Nevill T, Marcellus D, et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant. 2000;26:1179-1184.
114. Alyea E, Weller E, Schlossman R, et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood. 2001;98:934-939.
115. Bellucci R, Alyea EP, Weller E, et al. Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood. 2002;99:4610-4617.
116. Lokhorst HM, Wu K, Verdonck LF, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood. 2004; 103:4362-4364.
117. van de Donk NW, Kroger N, Hegenbart U, et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 2006;37:1135-1141.
118. Levenga H, Levison-Keating S, Schattenberg AV, et al. Multiple myeloma patients receiving preemptive donor lymphocyte infusion after partial T-cell-depleted allogeneic stem cell transplantation show a long progression-free survival. Bone Marrow Transplant. 2007;40:355-359.
119. Mitsiades CS, Mitsiades NS, Richardson PG, Munshi NC, Anderson KC. Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem. 2007;101:950-968.
120. Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008;68: 190-197.
121. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after non-myeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750-758.
122. Demirer T, Barkholt L, Blaise D, et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat Clin Pract Oncol. 2008;5:256-267.
123. Takahashi Y, Harashima N, Kajigaya S, et al. Regression of human kidney cancer following allo-geneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest. 2008;118:1099-1109.
124. Gratwohl A, Baldomero H, Demirer T, et al. Hematopoetic stem cell transplantation for solid tumors in Europe. Ann Oncol. 2004;15:653-660.
125. Barkholt L, Bregni M, Remberger M, et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol. 2006;17:1134-1140.
126. Suzuki Y, Adachi Y, Minamino K, et al. Anew strategy for treatment of malignant tumor: intra-bone marrow-bone marrow transplantation plus CD4- donor lymphocyte infusion. Stem Cells. 2005;23:365-370.
127. Koike Y, Adachi Y, Suzuki Y, et al. Allogeneic intrabone marrow-bone marrow transplantation plus donor lymphocyte infusion suppresses growth of colon cancer cells implanted in skin and liver of rats. Stem Cells. 2007;25:385-391.
128. Bishop MR, Fowler DH, Marchigiani D, et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol. 2004;22:3886-3892.
129. Klein CA, Wilke M, Pool J, et al. The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. J Exp Med. 2002;196:359-368.
130. Spiotto MT, Yu P, Rowley DA, et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 2002;17: 737-747.
131. Quin Z, Blankenstein T. CD4 T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN-g receptor expression by nonhematopoietic cells. Immunity. 2000;12: 677-686.
132. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100.
133. Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants: killer immunoglobulin-like receptor. Blood. 2002;100: 3825-3827.
134. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by adoptive transfer of T-cell clones. Science. 1992;257:238-241.
135. Rooney CM, Smith CA, Ng CYC, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345:9-13.
136. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202: 379-386.
137. Becker C, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-a capture assay. Nat Med. 2001;7:1159-1162.
138. Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood. 2004;103: 347-352.
139. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118:294-305.
140. Duell T, van Lint MT, Ljungman P, et al. Health and functional status of long-term survivors of bone marrow transplantation: EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med. 1997;126: 184-192.
141. Kolb HJ, Mittermüller J, Holler E, Thalmeier K, Bartram CR. Graft-versus-host reaction spares normal stem cells in chronic myelogenous leukemia. Bone Marrow Transplant. 1996;17:449-452.
142. Falkenburg JH, Goselink HM, van der Harst D, et al. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigenspecific cytotoxic T lymphocytes. J Exp Med. 1991;174:27-33.
143. Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR. CD8+ minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA. 1999;96:8639-8644.
144. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95:2198-2203.
145. Wu CJ, Biernacki M, Kutok JL, et al. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clin Cancer Res. 2005;11:4504-4511.
146. dem Borne PA, Luxemburg-Heijs SA, Heemskerk MH, et al. Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells. Leukemia. 2006;20:1040-1046.
147. Brouwer RE, van der HP, Schreuder GM, et al. Loss or downregulation of HLAclass I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon. Hum Immunol. 2002;63:200-210.
148. Hirano N, Takahashi T, Ohtake S, et al. Expression of costimulatory molecules in human leukemias. Leukemia. 1996;10:1168-1176.
149. Schneider EM, Chen ZZ, Ellwart J, Wilmanns W, Kolb HJ. Immune phenotype of chronic myelogenous leukemia progenitor cells [abstract]. Bone Marrow Transplant. 1996;17[Suppl]:69.
150. Schulz U, Munker R, Ertl B, Holler E, Kolb HJ. Different types of human leukemias express the message for TNF-alpha and interleukin-10. Eur J Med Res. 2001;6:359-363.
151. Pawelec G, Rehbein A, Schlotz E, da Silva P. Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro. Cancer Immunol Immunother. 1996;42:193-199.
152. Bergmann L, Schui DK, Brieger J, et al. The inhibition of lymphokine-activated killer cells in acute myeloblastic leukemia is mediated by transforming growth factor-beta 1. Exp Hematol. 1995;23: 1574-1580.
153. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117:1147-1154.
154. Molldrem JJ, Lee PP, Kant S, et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest. 2003;111:639-647.
155. Buggins AG, Hirst WJ, Pagliuca A, Mufti GJ. Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. Br J Haematol. 1998; 100:784-792.
156. Chen X, Woiciechowsky A, Raffegerst S, et al. Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Br J Haematol. 2000;111:817-825.
157. Trimble LA, Kam LW, Friedman RS, Xu Z, Lieberman J. CD3zeta and CD28 down-modulation on CD8 T cells during viral infection. Blood. 2000;96:1021-1029.
158. Shiobara S, Nakao S, Ueda M, et al. Donor leukocyte infusion for Japanese
159. Choi SJ, Lee JH, Lee JH, et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia. 2004;18:1789-1797.
160. Collins RH Jr, Goldstein S, Giralt S, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 2000;26:511-516.
161. Choi SJ, Lee JH, Lee JH, et al. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study. Bone Marrow Transplant. 2005;36:163-169.
162. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100:4310-4316.
163. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004;104:3865-3871.
164. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000;18:3031-3037.
165. Peggs KS, Mackinnon S, Williams CD, et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant. 2003;9: 257-265.
166. Huff CA, Fuchs EJ, Noga SJ, et al. Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biol Blood Marrow Transplant. 2003;9:312-319.
167. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/ recurrent mantle-cell lymphoma. J Clin Oncol. 2003;21:4407-4412.
168. Glass B, Nickelsen M, Dreger P, et al. Reduced-intensity conditioning before allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect. Bone Marrow Transplant. 2004;34:391-397.
169. Peggs KS, Sureda A, Qian W, et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol. 2007;139: 70-80.